Prof. dr. M.H.H. (Mark) Kramer

foto Kramer

ACADEMIC DEGREE: 1984 M.D. (cum laude) Leiden University and Medical school. Leiden, the Netherlands.

1997 Ph.D. Thesis University of Leiden:“Clinical correlates in aggressive Non-Hodgkins Lymphoma.”

ACADEMIC APPOINTMENTS:

2007-onwards Professor of Medicine and Chair department of Internal Medicine, Free University Medical Center, Amsterdam, the Netherlands.

PROFESSIONAL EXPERIENCE:

1983 -1984 Rotating Internship – Academisch ziekenhuis Leiden, the Netherlands.

1985-1986 Research Fellow Radiobiological Institute TNO, Rijswijk, the Netherlands (Prof. Dr D.W. van Bekkum): stem cell research.

1986 – 1988 Resident of Internal Medicine, Elisabeth Hospital, Willemstad, Curacao (N.A).

1988 – 1991 Resident of Internal Medicine, Academisch ziekenhuis Leiden, the Netherlands.

Board certified in 1991.

1991 – 1994 Senior physician – Department of Hematology-Bone marrow transplantation, Academisch ziekenhuis Leiden, the Netherlands.

1994 – 2007 Consultant Internal Medicine-Hematology, Meander Medical Center, Amersfoort, the Netherlands.

1994-2007 Director Anticoagulation Clinic Eemvallei, Amersfoort, the Netherlands.

2007-onwards Chair department of Medicine, Free University Medical Center, Amsterdam, the Netherlands.

RESEARCH INTERESTS:

General subject: a. Venous thromboembolism b. Diabetes mellitus

Specific subjects:

ad a) clinical studies on diagnosis and treatment of pulmonary embolism

ad a) clinical studies on diagnosis and treatment of post-thrombotic syndrome

ad b) the relation between vit D and diabetes

ad b) the genetic predisposition of diabetes in a cohort of twins

 

 

MAJOR PUBLIC PROFESSIONAL ACTIVITIES:

1994-onwards Fellow American Society of Hematology. Member Eur Soc Hematology

1999-2003 Member Forum Visitatorum, Netherlands Society Internal Medicine

2000-2007 Treasurer Netherlands Society of Haematology.

2000-2003 Board member Netherlands Society of Internal Medicine.

2000-onwards European Federation of Internal Medicine – Member of the administrative

council.

2003-onwards Board member Van Vlissingen Lymphoma Fund.

2004-2007 President Netherlands Society of Internal Medicine.

2004-2007 Netherlands Medical Specialist Association – member administrative council on Quality, Research and Medical Education.

2005 Honorary fellow American College of Physicians.

2006 Honorary fellow European Federation of Internal Medicine.

2006-2008 Netherlands Medical Specialist Association – member of the advisory committee ‘peer review of individual professionalism and behavior for medical specialists’.

2009-onwards Chairman committee on “Professional issues on Internal Medicine’, European Society of Internal Medicine

2009 Fellow Royal College of Physicians

PUBLICATIONS (last five years) – from 2004.

1. A case of cocaine-induced panhypopituitarism with human neutrophil elastase-specific anti-neutrophil cytoplasmic antibodies. de Lange TE, Simsek S, Kramer MHH, Nanayakkara PW. Eur J Endocrinol. 2009 Mar;160(3):499-502. Epub 2008 Dec 29.

2. Djurabi RK, Klok FA, Nijkeuter M, Kaasjager K, Kamphuisen PW, Kramer MHH, Kruip MJ, Leebeek FW, Büller HR, Huisman MV. Comparison of the clinical usefulness of two quantitative D-Dimer tests in patients with a low clinical probability of Pulmonary Embolism. Thromb Res. 2009;123(5):771-4. Epub 2008 Sep 24

3. Acetylsalicylic acid does not prevent cardiovascular diseases in diabetic patients. Kramer MHH. Ned Tijdschr Geneeskd. 2009 Feb 14;153(7):291

4. Excluding pulmonary embolism without imaging tests–can our diagnostic algorithm be optimized? Nijkeuter M, Tick LW, Sohne M, Kruip MJ, Buller HR, Leebeek FW, Kramer MHH, Klok FA, Prins MH, Huisman MV; Christopher Study Investigators. Thromb Haemost. 2008 Dec;100(6):1203-6

5. Imatinib-induced pseudoporphyria. Timmer-de Mik L, Kardaun SH, Kramer MHH, Hayes DP, Bousema MT. Clin Exp Dermatol. 2008 Dec 9. [Epub ahead of print]

6. Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis.Tick LW, Kramer MHH, Rosendaal FR, Faber WR, Doggen CJ. J Thromb Haemost. 2008 Dec;6(12):2075-81. Epub 2008 Oct 4.

7. The interaction between anticoagulant therapy with vitamin K-antagonists and treatment with antibiotics: a practical recommendation. Zelis M, Zweegman S, van der Meer FJ, Kramer MHH, Smulders YM. Ned Tijdschr Geneeskunde. 2008;3;152(18):1042-6.

8. High D-dimer levels increase the likelihood of pulmonary embolism. Tick LW, Nijkeuter M, Kramer MHH, Hovens MM, Büller HR, Leebeek FW, Huisman MV; on behalf of the Christopher Study Investigators. Intern Med. 2008 Aug;264(2):195-200.

9. An early switch from intravenous to oral antibiotics is equally effective as the standard intravenous therapy in severe community acquired pneumonia. Oosterheert JJ, Bonten MJ, Schneider MM, Buskens E, Lammers JW, Hustinx WN, Kramer MHH, Prins JM, Slee PT, Kaasjager K, Hoepelman IM. Ned Tijdschr Geneeskunde 2008;152(5):269-74. Erratum in: Ned Tijdschr Geneeskunde 2008;23;152(8):472.

10. High D-dimer level is associated with increased 15-d and 3 months mortality through a more central localization of pulmonary emboli and serious comorbidity. Klok FA, Djurabi RK, Nijkeuter M, Eikenboom HC, Leebeek FW, Kramer MHH, Kaasjager K, Kamphuisen PW, Büller HR, Huisman MV. Br J Haematol. 2008;140(2):218-22. Epub 2007 Nov 19.

11. Vaccination responses and lymphocyte subsets after autologous stem cell transplantation. van der Velden AM, Claessen AM, van Velzen-Blad H, de Groot MR, Kramer MHH, Biesma DH, Rijkers GT. Vaccine 2007;12;25(51):8512-7. Epub 2007 Oct 25.

12. Arterial thrombosis and the role of thrombophilia. Boekholdt SM, Kramer MHH. Semin Thromb Hemost 2007;33:588-596

13. Extreme leucocytosis: not always leukaemia. Haklkes CJ, Dijstelbloem HM, Eelkman Rooda SJ, Kramer MHH. Neth J Med 2007;65:248-251

14. Clinically suspected acute recurrent pulmonary embolism: a diagnostic challenge. Nijkeuter M, Kwakkel-van Erp H, Sohne M, Tick LW, Kruip MJ, Ullmann EF, Kramer MHH, Buller HR, Prins MH, Leebeek FW, Huisman MV; on behalf of the Christopher Study Investigators. Thromb Haemost. 2007;97(6):944-8.

15. Intensified CHOP of 12-weeks duration (I-CHOP) plus G-CSF compared with standard CHOP of 24-weeks duration (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin’s Lymphoma. A phase III trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Verdonck LF, Noteboom A, de Jong DD, Mackenzie MA, Verweij GE, Kramer MHH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, van Imhoff GW. Blood. 2007 Apr 1;109(7):2759-66.

16. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. Schalekamp T, van Geest-Daalderop JH, Kramer MHH, van Holten-Verzantvoort AT, de Boer A. Eur J Clin Pharmacol. 2007 Apr;63(4):335-43. Epub 2007 Feb 21.

17. The natural course of hemodynamically stable pulmonary embolism: Clinical outcome and risk factors in a large prospective cohort study. Nijkeuter M, Sohne M, Tick LW, Kamphuisen PW, Kramer MHH, Laterveer L, van Houten AA, Kruip MJ, Leebeek FW, Buller HR, Huisman MV. Chest. 2007 Feb;131(2):517-23.

18. Blue rubber bleb nevus syndrome co-existing with celiac disease. Oosterheert JJ, Bousema MT, Lagendijk J, Kramer MHH. Neth J Med. 2006 Dec;64(11):431-4.

19. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. Oosterheert JJ, Bonten MJ, Schneider MM, Buskens E, Lammers JW, Hustinx WM, Kramer MHH, Prins JM, Slee PH, Kaasjager K, Hoepelman AI. BMJ 2006;9:1193-96

20. The blue rubber bleb nevus syndrome co-existing with celiac disease. Oosterheert JJ, Bousema MT, Kramer MHH. Neth J Med 2006;64:431-434

21. A simple diagnostic strategy in hospitalized patients with clinically suspected pulmonary embolism. MJHA Kruip, M. Söhne, M Nijkeuter, HM Kwakkel-van Erp, LW Tick, SJM Halkes, MH Prins, Kramer MHH, MV Huisman, HR Büller, FWG Leebeek on behalf of the Christopher Study Investigators. J Intern Med 2006;260: 459–466

22. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. Van Belle A, Buller HR, Huisman MV, Huisman PM, Kaasjager K, Kamphuisen PW, Kramer MHH, Kruip MJ, Kwakkel-van Erp JM, Leebeek FW, Sohne M, Tick LW, Christopher Study Investigators, JAMA 2006;11:295(2):172-9

23. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Van der Spek E, Bloem AC, van de Donk NW, Bogers LH, Kramer MHH, de Weerdt O, Wittebol S, Lokhorst HM. Hematologica 2006;91(4):542-5.

24. The value of integrated PET-CT images in 2 lymphoma patients with skeletal localisations. Geerts MC, Quarles van Ufford HME, Kramer MHH, van Waes PFGM, de Klerk JMH. Ned Tijdschr Geneeskunde 2006;150:204-9

25. Cost analysis of common treatment options for indolent follicular lymphoma. Agthoven M, Kramer MHH, Sonneveld P, Hem vd K, Huijgens PC, Wijermans P, Kluin-Nelemans HC, Schaafsma MR, Biesma DH, Mattijssen V, Uyl-de Groot CA, Hagenbeek A. Haematologica/the Hematology Journal 2005;90(10):1422-32

26. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. van Imhoff GW, van der Holt B, Mackenzie MA, Ossenkoppele GJ, Wijermans PW, Kramer MHH, van ’t Veer MB, Schouten HC, van Marwijk Kooy M, van Oers MH, Raemaekers JM, Sonneveld P, Meulendijks LA, Kluin PM, Kluin-Nelemans HC, Verdonck LF. Leukemia 2005;19:945-952

27. Political issues in internal medicine in Europe. A position paper. Bauer W, Schumm-Draeger P-M, Koebberling J, Gjoerup T, Garcia Allegra, JJ, Higgins C, Kramer MHH, Licata A, Mittelman M, O’Hare J, Unal S. Eur J Int Med 2005; 16:214-17

28. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MHH, Castro JE, Kipps TJ, van Lier RA, van Oers MH, Eldering E. Leukemia 2005;19(3):427-34

 

29. Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukemia: a randomised phase II trial from HOVON. Daenen S, Holt B, Verhoef G, Löwenberg B, Wijermans P, Huijgens P, Marwijk Kooy R, Schouten H, Kramer MHH, Ferrant A, Berg E, Steijaart M, Verdonck L, Sonneveld P. Leukemia Research 2004;28:1057-1067

30. Acquired and inherited thrombophilic factors and the risk for residual venous thrombosis. Bank I, Tick LW, Hutten BA, Kramer MHH, Middeldorp S, Buller HR. Pathophysiol Haemost Thromb 2004;33(4):192-6.

31. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymhocytic leukemia. Rossi JF, van Hoof A, de Boeck K, Johnson SA, Bron D, Foussard C, Lister TA, Berthou C, Kramer MHH, Littlewood TJ, Marcus RE, Deconinck E, Montillo M, Guibon O, Tollerfield SM. J Clin Oncol 2004;22(7):1260-7

32. Survival of patients with aggressive non-hodgkin’s lymphoma: no difference between first line treatment in a prospective randomised phase III clinical trial and first line treatment according to routine clinical practice. Van Agthoven M, Wittebol S, Budel LM, Uyl-de Groot CA, Kramer MHH. Ned Tijdschr Geneeskunde 2004;148(2):88-93

33. Lack of prognostic significance of bcl2 and p53 protein overexpression in elderly patients with diffuse large B-cell lymphoma: results from a population-based Non-Hodgkin’s lymphoma registry. Maartense E, Kramer MHH, Le Cessie S, Kluin-Nelemans JC, Snijder S, Noordijk EM. Leuk & Lymph 2004;45:101-7